United Therapeutics (UTHR) Price & Analysis

Compare

653 Followers

UTHR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$266.98 - $436.95

Previous CloseN/A

Volume58.00K

Average Volume (3M)906.37K

Market Cap

$17.85B

Enterprise Value$10.83B

Total Cash (Recent Filing)$3.05B

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)15.8

Beta0.49

Next Earnings

Oct 29, 2025

EPS Estimate

7.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)6.41

Shares Outstanding45,226,260

10 Day Avg. Volume1,189,192

30 Day Avg. Volume906,372

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.61

Enterprise Value/Revenue3.52

Enterprise Value/Gross Profit3.95

Enterprise Value/Ebitda6.52

Forecast

1Y Price Target

$487.90

Price Target Upside20.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Efficacy And Clinical ResultsTyvaso demonstrated a clinically meaningful 95.6 mL treatment effect vs placebo in absolute FVC.

Market PotentialPotential expansion into the approximately 100K US IPF patient population creates significant added runway for the Tyvaso franchise beyond existing PAH/PH-ILD markets.

Regulatory AdvancementsUTHR plans to meet with the FDA to discuss ways to potentially expedite the regulatory review process for Tyvaso.

Bears Say

CompetitionDPI and nebulized Tyvaso continue to face near-term competition risk.

Usage RegimenTyvaso has the disadvantage of a 4x-daily inhalation regimen compared to competitor's oral dosing.

United Therapeutics News

United Therapeutics price target raised to $525 from $405 at Cantor Fitzgerald

Cantor Fitzgerald analyst Olivia Brayer raised the firm’s price target on United Therapeutics (UTHR) to $525 from $405...

15h ago

UTHR

United Therapeutics price target raised to $575 from $510 at Oppenheimer

Oppenheimer raised the firm’s price target on United Therapeutics (UTHR) to $575 from $510 and keeps an Outperform...

6d ago

UTHR

United Therapeutics price target raised to $500 from $400 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on United Therapeutics (UTHR) to $500 from $400...

6d ago

UTHR

United Therapeutics price target raised to $560 from $415 at UBS

UBS raised the firm’s price target on United Therapeutics (UTHR) to $560 from $415 and keeps a Buy...

7d ago

UTHR

United Therapeutics Stock (UTHR) Rockets 40% on Clinical Trial Results

United Therapeutics stock surged on Tuesday after it reported positive Phase 3 clinical trial results. ...

8d ago

UTHR

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Investors are back in the saddle after an extended weekend, and there’s plenty of stock market news to catch up on. ...

8d ago

AMD

BLK

Kraft Heinz announces separation, Elliott builds $4B PepsiCo stake: Morning Buzz

The major averages were broadly lower near noon following the long weekend. Investors are weighing the latest developments...

8d ago

United Therapeutics rises 34.6%

United Therapeutics (UTHR) is up 34.6%, or $105.59 to $410.35. Published first on TheFly – the ultimate source...

8d ago

UTHR

United Therapeutics price target raised to $463 from $314 at BofA

BofA raised the firm’s price target on United Therapeutics (UTHR) to $463 from $314 and keeps a Neutral...

8d ago

LQDA

UTHR

United Therapeutics price target raised to $564 from $432 at Jefferies

Jefferies analyst Roger Song raised the firm’s price target on United Therapeutics (UTHR) to $564 from $432 and...

9d ago

UTHR

United Therapeutics rises 42.1%

United Therapeutics (UTHR) is up 42.1%, or $128.24 to $433.00. Published first on TheFly – the ultimate source...

9d ago

UTHR

Insmed strength on United Therapeutics read through ‘warranted,’ says BofA

BofA notes Insmed (INSM) shares were strong in pre-market trading following United Therapeutics’ (UTHR) announcement that TETON-2, its...

9d ago

INSM

UTHR

Buy Rating for United Therapeutics: Promising TETON-2 Trial Results Highlight Tyvaso’s Potential in IPF Treatment

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on UTHR stock, giving a Buy rating yesterday....

7d ago

UTHR

United Therapeutics’ Tyvaso Shines in Phase III Trial, Poised for Growth in IPF Market

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on UTHR stock, giving a Buy rating yesterday....

8d ago

UTHR

UTHR FAQ

What was United Therapeutics’s price range in the past 12 months?

United Therapeutics lowest stock price was $266.98 and its highest was $436.95 in the past 12 months.

What is United Therapeutics’s market cap?

United Therapeutics’s market cap is $17.85B.

When is United Therapeutics’s upcoming earnings report date?

United Therapeutics’s upcoming earnings report date is Oct 29, 2025 which is in 48 days.

How were United Therapeutics’s earnings last quarter?

United Therapeutics released its earnings results on Jul 30, 2025. The company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $7.295 by -$0.885.

Is United Therapeutics overvalued?

According to Wall Street analysts United Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does United Therapeutics pay dividends?

United Therapeutics does not currently pay dividends.

What is United Therapeutics’s EPS estimate?

United Therapeutics’s EPS estimate is 7.33.

How many shares outstanding does United Therapeutics have?

United Therapeutics has 45,226,260 shares outstanding.

What happened to United Therapeutics’s price movement after its last earnings report?

United Therapeutics reported an EPS of $6.41 in its last earnings report, missing expectations of $7.295. Following the earnings report the stock price went down -5.246%.

Which hedge fund is a major shareholder of United Therapeutics?

Currently, no hedge funds are holding shares in UTHR

United Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

19.30%

Trailing 12-Months

Asset Growth

17.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet needs of patients with chronic and life-threatening conditions. The company operates primarily in the pulmonary and vascular disease sectors, offering therapies for conditions such as pulmonary arterial hypertension (PAH) and organ transplantation. Its core products include Remodulin, Tyvaso, and Orenitram, which are designed to improve the quality of life for patients suffering from these serious health issues.

United Therapeutics (UTHR) Earnings & Revenues

Historic Earnings Reports

UTHR Company Deck

UTHR Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a balanced perspective with strong financial results and strategic initiatives, including record revenue growth and pipeline advancements. However, competitive challenges and concerns regarding market perceptions and regulatory hurdles were also highlighted.View all UTHR earnings summaries

UTHR Revenue Breakdown

53.01% Tyvaso

21.26% Remodulin

15.44% Orenitram

8.55% Unituxin

1.75% Other

UTHR Stock 12 Month Forecast

Average Price Target

$487.90

▲(20.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"289":"$289","576":"$576","360.75":"$360.8","432.5":"$432.5","504.25":"$504.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$575.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":487.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$487.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":328,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$328.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[289,360.75,432.5,504.25,576],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,404.81,417.90153846153845,430.9930769230769,444.0846153846154,457.17615384615385,470.2676923076923,483.35923076923075,496.4507692307692,509.5423076923077,522.6338461538462,535.7253846153847,548.8169230769231,561.9084615384616,{"y":575,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,404.81,411.20153846153846,417.5930769230769,423.9846153846154,430.37615384615384,436.7676923076923,443.15923076923076,449.5507692307692,455.9423076923077,462.33384615384614,468.7253846153846,475.11692307692306,481.5084615384615,{"y":487.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,404.81,398.90153846153845,392.9930769230769,387.0846153846154,381.17615384615385,375.2676923076923,369.35923076923075,363.45076923076925,357.5423076923077,351.63384615384615,345.7253846153846,339.8169230769231,333.90846153846155,{"y":328,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":363.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":357.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":374.02,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":370.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":352.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":351.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":320.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":306.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":293.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >